Skip to navigation Skip to main content

Your search for tofacitinib returned 11 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Post remove
News remove

Your search for tofacitinib returned 11 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Tofacitinib Effective in Phase 3 Psoriasis Retreatment Study

Publish Date
Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
News

Methotrexate Monotherapy, Combo Therapy Compared for RA

Publish Date
Researchers from the University of Calgary found moderate to high quality evidence that triple therapy with methotrexate + sulfasalazine + hydroxycholoroquine or combining methotrexate + most biologic disease-modifying antirheumatic drug (DMARDs) or tofacitinib demonstrated similar efficacy in controlling disease activity in methotrexate-naive patients or after an inadequate response to methotrexate.
News

Tofacitinib Goes Head-to-Head with Adalimumab in RA Study

Publish Date
Tofacitinib plus MTX was shown to be non-inferiority vs. adalimumab plus MTX, however, Xeljanz monotherapy did not meet its primary endpoint for non-inferiority vs.adalimumab plus MTX, or vs. Xeljanz plus MTX.
News

Xeljanz Label Gains Radiographic Data Addition

Publish Date
Pfizer announced that the FDA has approved a sNDA to update the current label of Xeljanz (tofacitinib citrate) tablets to include radiographic data from two Phase 3 studies, ORAL Scan and ORAL Start.